LOGOLOGOLOGOLOGO
  • About us
    • Who we are
      • Governance
      • Staff
      • Vacancies
    • What we do
  • Members
    • EuropaBio Members
    • About Membership
  • How we work
    • Healthcare Biotechnology Council
      • Medicines For Rare Diseases And Children
      • Patient Bio-Forum
    • Industrial Biotechnology Council
      • Food, Feed & Nutrition
      • Circular Bioeconomy
    • National Associations Council
    • SME Platform
    • Biomanufacturing Platform
  • Activities
    • 25 Years of Innovation
    • EFIB
    • European Biotech Week
  • News & Events
    • News
    • Events
  • Library
Become a member
✕

“Buying Innovative” in the Healthcare Biotech Market in Europe

02/02/2017
REPORT

"Buying Innovative" in the Healthcare Biotech Market in Europe

With regard to the healthcare biotechnology sector “buying innovative” means organising a public procurement process in a way that ensures a balance between the various public health objectives, i.e. securing access for patients to innovative therapies, guaranteeing high standards of quality, safety and efficacy of products purchased, and incentivising companies to compete in a free and dynamic internal market. More specifically in a way that:

• Reflects patients’ needs and offers freedom of choice for doctors/patients, by ensuring that treatment options are not limited and decisions can always be made by a physician in consultation with patients. Given the recognised differences between biological medicines, a variety of biological medicines should be available for patients, not only a single medicine.
• Respects physicians’ prescribing authority as regards decisions to keep treated patient with their current treatments or to alternate therapies. The decision to switch a patient to a new product should only be taken by the prescribing doctor in alignment with the patient and not be based on the results of a tendering process or purely on economic considerations.
• Takes into account the complexity of biological medicines, including manufacturing practices, and for instance allows for sufficient lead times between an award decision and product delivery.
• It is awarded based on careful consideration of additional criteria besides price, such as manufacturer experience, long-term efficacy and safety data, the need to ensure continuity of treatment, quality, services, manufacturing and reliability of supply as well as outcomes and additional potential costs (e.g. hospitalisations) incurred by patients and healthcare professionals during the course of previous therapeutic plans.
• Fosters fair market competition and innovation, for instance by ensuring all manufacturers are able to compete with other bids and/or negotiate with payers on an equal footing.

Download the full publication below.

“Buying Innovative” in the Healthcare Biotech Market in Europe


Download
Share
Alexandra Simionca
Alexandra Simionca

Related posts

16/11/2023

Wojciech Nowak, Novartis, appointed as new Chair of EuropaBio’s Healthcare Council


Read more
02/11/2023

Factsheet – Supporting small biotechs in the revision of EU pharmaceutical legislation


Read more
30/10/2023

The European Life Science Investment Attractiveness Report Fourth Edition 2023 Time to Act


Read more

Important links

  • Wojciech Nowak, Novartis, appointed as new Chair of EuropaBio’s Healthcare Council
  • Factsheet – Supporting small biotechs in the revision of EU pharmaceutical legislation

Categories in our Newsroom

Subscribe for our newsletter

Subscribe to the EuropaBio newsletter to receive the latest news and developments in the Biotech sector!


Subscribe
EBIO-white

EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 2600 biotech companies, 2300 out of them are SMEs.

Contact us

Extra links

Members
Staff
Privacy policy
Legal & cookies
Events
Newsroom

Become a member

Media pack

© 2023 Europabio. All Rights Reserved. Designed by EYAS
Become a member